Inhibition of neutrophilic inflammation by targeting the airway epithelial barrier with EP395.
J. Kricker (Reykjavík, Iceland), F. Gardarsson (Reykjavík, Iceland), F. Lehmann (Reykjavík, Iceland), M. Bech (Reykjavík, Iceland), T. Gudjonsson (Reykjavík, Iceland), C. Page (London, United Kingdom), M. Parnham (Reykjavík, Iceland)
Source: International Congress 2022 – Identifying therapeutic targets and novel drug strategies in pulmonary diseases
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Kricker (Reykjavík, Iceland), F. Gardarsson (Reykjavík, Iceland), F. Lehmann (Reykjavík, Iceland), M. Bech (Reykjavík, Iceland), T. Gudjonsson (Reykjavík, Iceland), C. Page (London, United Kingdom), M. Parnham (Reykjavík, Iceland). Inhibition of neutrophilic inflammation by targeting the airway epithelial barrier with EP395.. 2838
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|